Appendix A

Tables

A-1

 

Historical Review of the Biomarker–Surrogate Endpoint Literature with Special Reference to the Nomenclature, Initial Reports, Systems of Classification, and Statistical Methods Developed for Their Evaluation,

 

252

A-2

 

Continuation of Table A-1 for 2007–2009,

 

267

Appendix B

Boxes

B-1

 

Summary of Recommendations to Develop Biomarker-Based Tools for Cancer,

 

278

B-2

 

Summary of Recommendations for The Future of Drug Safety: Promoting and Protecting the Health of the Public,

 

279



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement